BMS-963272   Click here for help

GtoPdb Ligand ID: 12738

Synonyms: BMS963272 | compound 21s [PMID: 34613725]
Compound class: Synthetic organic
Comment: BMS-963272 is an inhibitor of monoacylglycerol O-acyltransferase 2 (MGAT2) [2] that was designed to treat inflammation and fibrosis that is associated with metabolic disorders [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 87.44
Molecular weight 525.45
XLogP 4.99
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC=C(C=C1)C2=C(C3=NN=NN3)C(=O)N[C@@](C2)(C4=CC=C(C=C4)OCCCC(F)(F)F)C(F)(F)F
Isomeric SMILES O=C1N[C@@](CC(C2=CC=C(C=C2)C)=C1C3=NN=NN3)(C4=CC=C(OCCCC(F)(F)F)C=C4)C(F)(F)F
InChI InChI=1S/C24H21F6N5O2/c1-14-3-5-15(6-4-14)18-13-22(24(28,29)30,31-21(36)19(18)20-32-34-35-33-20)16-7-9-17(10-8-16)37-12-2-11-23(25,26)27/h3-10H,2,11-13H2,1H3,(H,31,36)(H,32,33,34,35)/t22-/m0/s1
InChI Key AEMPUAWUDAMJBV-QFIPXVFZSA-N
No information available.
Summary of Clinical Use Click here for help
BMS-963272 was advanced to clinical evaluation as an oral therapy for diabetes mellitus and non-alcoholic fatty liver disease.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04766476 A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease Phase 1 Interventional Bristol-Myers Squibb
NCT02327273 Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects Phase 1 Interventional Bristol-Myers Squibb